FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1193 March 16, 2006 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Supplementary Material Editorial by Curfman, G. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

On December 8, 2005, we published an expression of concern¹ regarding an article by Bombardier et al. on the Vioxx Gastrointestinal Outcomes Research (VIGOR) study that was published in the Journal on November 23, 2000.² Our expression of concern was prompted by evidence that the VIGOR article did not accurately represent the safety data available to the authors when the article was being reviewed for publication.

More than four months before the article was published, at least two of its authors were aware of critical data on an array of adverse cardiovascular events that were not included in the VIGOR . . . [Full Text of this Article]

Source Information

This letter was published at www.nejm.org on February 22, 2006.

This article has been cited by other articles:

• Chan, A.-W., Hrobjartsson, A., Jorgensen, K. J, Gotzsche, P. C, Altman, D. G (2008). Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 337: a2299-a2299 [Abstract] [Full Text]  
• Chalkidou, K., Lord, J., Fischer, A., Littlejohns, P. (2008). Evidence-Based Decision Making: When Should We Wait For More Information?. Health Aff (Millwood) 27: 1642-1653 [Abstract] [Full Text]  
• Troy, D. E., Gottlieb, S., Kesselheim, A. S., Avorn, J. (2008). Pharmaceutical Promotion and First Amendment Rights. NEJM 359: 536-537 [Full Text]  
• Greenland, S. (2007). Commentary: On 'Quality in epidemiological research: should we be submitting papers before we have the results and submitting more hypothesis generating research?'. Int J Epidemiol 36: 944-945 [Full Text]  
• Psaty, B. M., Charo, R. A. (2007). FDA Responds to Institute of Medicine Drug Safety Recommendations--In Part. JAMA 297: 1917-1920 [Full Text]  
• Criner, G. J. (2007). Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials. Proc Am Thorac Soc 4: 171-175 [Abstract] [Full Text]  
• Coultas, D. (2007). Ethical Considerations in the Interpretation and Communication of Clinical Trial Results. Proc Am Thorac Soc 4: 194-199 [Abstract] [Full Text]  
• Laine, C., Goodman, S. N., Griswold, M. E., Sox, H. C. (2007). Reproducible Research: Moving toward Research the Public Can Really Trust. ANN INTERN MED 146: 450-453 [Abstract] [Full Text]  
• Glick, M. (2006). Opprobrium or opportunity?. Journal of the American Dental Association 137: 1484-1486 [Full Text]  
• Zhang, J., Ding, E. L., Song, Y. (2006). Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. JAMA 296: 1619-1632 [Abstract] [Full Text]  
• DeAngelis, C. D. (2006). The Influence of Money on Medical Science. JAMA 296: 996-998 [Full Text]  
• Psaty, B. M., Rennie, D. (2006). Clinical Trial Investigators and Their Prescribing Patterns: Another Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry. JAMA 295: 2787-2790 [Full Text]  
• Dieppe, P. (2006). Complicity theory: an explanation for the ;coxib problem'?. JRSM 99: 273-274 [Full Text]